Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer and begins in the cells lining the ...

A new study by the National Cancer Research Center (CNIO) has identified several sets of genes related to the predisposition ...

Please provide your email address to receive an email when new articles are posted on . Chronic HCV infection was associated with a 1.8-fold increased risk for pancreatic ductal adenocarcinoma.

Pancreatic ductal adenocarcinoma (PDAC) is the most lethal form of pancreas cancer. It's also the most common form of the ...

From 1993 to 2008, 195 patients underwent pancreatic head resections (PD) due to ductal adenocarcinoma of the pancreas at our institution. The patients were observed from 1993 to 2011. The patient ...

Dr. Schwartz answers the question: 'Difference between in situ breast cancers?' — -- Question: What is the difference between ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS)?

Efficacy and safety of FOLFIRINOX versus gemcitabine-based regimens for treatment of metastatic pancreatic cancer: A systematic review and meta-analysis. This is an ASCO Meeting Abstract from the 2025 ...

HUTCHMED has commenced the Phase III stage of its ongoing Phase II/III clinical trial assessing the combination of ...

SAN FRANCISCO -- Almost 80% of patients with heavily pretreated advanced/metastatic pancreatic cancer achieved disease ...

Ductal adenocarcinoma of the prostate is a rare, yet aggressive, subtype of prostate cancer that diverges in clinicopathological and genomic characteristics from the more common acinar adenocarcinoma.